AR050184A1 - Inhibidores macrociclicos de beta-secretasa - Google Patents

Inhibidores macrociclicos de beta-secretasa

Info

Publication number
AR050184A1
AR050184A1 ARP050103099A ARP050103099A AR050184A1 AR 050184 A1 AR050184 A1 AR 050184A1 AR P050103099 A ARP050103099 A AR P050103099A AR P050103099 A ARP050103099 A AR P050103099A AR 050184 A1 AR050184 A1 AR 050184A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
aryl
heterocyclyl
aralkyl
Prior art date
Application number
ARP050103099A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR050184A1 publication Critical patent/AR050184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP050103099A 2004-07-28 2005-07-26 Inhibidores macrociclicos de beta-secretasa AR050184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59189904P 2004-07-28 2004-07-28

Publications (1)

Publication Number Publication Date
AR050184A1 true AR050184A1 (es) 2006-10-04

Family

ID=35106859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103099A AR050184A1 (es) 2004-07-28 2005-07-26 Inhibidores macrociclicos de beta-secretasa

Country Status (12)

Country Link
US (2) US7652003B2 (cg-RX-API-DMAC7.html)
EP (1) EP1781644B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008508289A (cg-RX-API-DMAC7.html)
CN (1) CN101027297B (cg-RX-API-DMAC7.html)
AR (1) AR050184A1 (cg-RX-API-DMAC7.html)
AT (1) ATE396990T1 (cg-RX-API-DMAC7.html)
CA (1) CA2575340A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005007245D1 (cg-RX-API-DMAC7.html)
ES (1) ES2306200T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007001102A (cg-RX-API-DMAC7.html)
TW (1) TWI297337B (cg-RX-API-DMAC7.html)
WO (1) WO2006014944A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0606636A2 (pt) * 2005-01-13 2009-07-07 Novartis Ag compostos macrocìclicos úteis como inibidores de bace
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
ATE482214T1 (de) * 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20090041387A (ko) * 2006-07-20 2009-04-28 노파르티스 아게 마크로시클릭 락탐
EP2073635B1 (en) 2006-10-06 2012-03-21 Merck Sharp & Dohme Corp. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2379566A2 (en) 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
ES2745539T3 (es) 2012-03-19 2020-03-02 Buck Inst Res Aging Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
CN105175488A (zh) * 2015-09-07 2015-12-23 西北农林科技大学 一种具有抗老年痴呆症活性的化合物及其制备方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI902006A7 (fi) 1987-10-21 1990-04-20 Upjohn Co Menetelmä renniini-inhibiittoreiden valmistamiseksi, jotka sisältävät 1-amino-2-hydroksi-2-heterosyklisen etyylitähteen
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス ファーマシューティカルズ インコーポレイテッド Baceのインヒビター
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
JP2004534064A (ja) * 2001-06-12 2004-11-11 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
DE60329316D1 (de) * 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EP1583750B1 (en) * 2003-01-07 2013-02-27 Merck Sharp & Dohme Corp. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
CA2579724A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
CA2578600A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
BRPI0613578A2 (pt) 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
RU2008106936A (ru) 2005-09-26 2009-11-10 Вайет (Us) Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ 2−アミノピリミジン−4−オン及びAβ−関連の病理を治療又は予防するためのその使用
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
ATE396990T1 (de) 2008-06-15
CN101027297A (zh) 2007-08-29
CN101027297B (zh) 2010-09-08
EP1781644A1 (en) 2007-05-09
ES2306200T3 (es) 2008-11-01
US20100178294A1 (en) 2010-07-15
WO2006014944A1 (en) 2006-02-09
HK1102328A1 (en) 2007-11-16
EP1781644B1 (en) 2008-05-28
DE602005007245D1 (cg-RX-API-DMAC7.html) 2008-07-10
US8012953B2 (en) 2011-09-06
MX2007001102A (es) 2007-04-13
TW200607807A (en) 2006-03-01
US20060040948A1 (en) 2006-02-23
US7652003B2 (en) 2010-01-26
CA2575340A1 (en) 2006-02-09
JP2008508289A (ja) 2008-03-21
TWI297337B (en) 2008-06-01

Similar Documents

Publication Publication Date Title
AR049726A1 (es) Amidas sustituidas inhibidoras de beta secretasa
Ruchelman et al. 11H-Isoquino [4, 3-c] cinnolin-12-ones: novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity
US11124516B2 (en) Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP5584626B2 (ja) 2−アルキルアミノ−3−(アリールスルホニル)−シクロアルキル[e又はd]ピラゾロ[1,5−a]ピリミジン−セロトニン5−HT6受容体アンタゴニスト、その調製の方法及び使用
JP5584627B2 (ja) 置換されたシクロアルキル[e又はd]ピラゾロ[1,5−a]ピリミジン−セロトニン5−HT6受容体のアンタゴニスト、その調製の方法及び使用
EA006815B1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
PT94806A (pt) Processo para a preparacao de agentes antipsicoticos espirociclicos
KR20050087865A (ko) HIV 인테그라제 억제제로서 유용한테트라하이드로-4H-피리도[1,2-a]피리미딘 및 관련화합물
JP2009513495A (ja) 癌の治療において有効な新規のピロロジヒドロイソキノリン
EP4110340A1 (en) Potent and selective degraders of alk
CA3109617A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
EP1996550A2 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
JP2015529252A (ja) フルオロアルキル−1,4−ベンゾジアゼピノン化合物
JP2008508289A5 (cg-RX-API-DMAC7.html)
KR20020089372A (ko) 알파-2 길항제로서의 퀴놀린 유도체
JP2009539936A (ja) ピラゾロピリミドン
JP2002541144A (ja) 医薬的に活性のある化合物及びその使用方法
JP2012516333A (ja) Hivインテグラーゼ阻害剤としての架橋化合物
AR032475A1 (es) Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende
ES2255483T3 (es) 6-arilfenantridinas con actividad inhibidora de pde-iv.
JP2018522058A (ja) 化合物
JP5575663B2 (ja) 置換された2−アミノ−3−(スルホニル)ピラゾロ[1,5−a]ピリミジン−セロトニン5−HT6受容体アンタゴニスト、その調製のための方法及び使用
JP2019535680A (ja) キナーゼを阻害する組成物及び方法
JP2011519921A (ja) テトラヒドロピラゾロ[1,5−a]ピリド−ピリミジン−セロトニン5−HT6受容体アンタゴニスト、その調製のための方法及び使用
WO2020210337A1 (en) Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal